Contrarian Opinion: Tariffs, Inflation, and Recession Fears Could Be a Tailwind for This Retail Stock and Propel It to a $1 Trillion Valuation
President Trump's new tariffs could cause prices to rise for consumers and induce a period of slowing economic growth.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ibotta - Ibotta ( NYSE:IBTA )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Ibotta To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex - Zynex ( NASDAQ:ZYXI )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options
Crypto sentiment recovers, but weekend liquidity risks remain
Crypto investor sentiment has seen a significant recovery from global tariff concerns, but analysts warn that the market's structural weaknesses may still result in downside momentum during periods of weekend illiquidity.Risk appetite appeared to return among crypto investors this week after US ...
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SoundHound AI - SoundHound AI ( NASDAQ:SOUN )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In SoundHound AI To Contact Him Directly To Discuss Their Options
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
NEW YORK, April 26, 2025 ( GLOBE NEWSWIRE ) -- Protara Therapeutics, Inc. ( Nasdaq: TARA ) , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing ...
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - Protara Therapeutics ( NASDAQ:TARA )
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients
Andrew Ng Explains Why You Should Stop Overthinking AI Prompts - 'Most LLMs Are Smart Enough To Figure Out What You Want'
Artificial intelligence may be advancing faster than users can keep up-and according to AI pioneer Andrew Ng, the secret to working better with it might be doing less.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Geron ( NASDAQ:GERN )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options
